|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A G>A variation in the pre‑miR‑34a coding region was found to be associated with higher OS morbidity.
|
25242229 |
2014 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
lncRNA C2dat1 Promotes Cell Proliferation, Migration, and Invasion by Targeting miR-34a-5p in Osteosarcoma Cells.
|
28810936 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, the findings in our study highlight that cyclin A2 repression by miRNAs of the miR-16 and miR-34 families is lost in aggressive OS.
|
30679313 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
And the expression of C-IAP2 and Bcl-2 protein was drastically inhibited, and the activities of caspase-3 and caspase-9 were significantly increased after transfecting miR-34a onto osteosarcoma MG-63 cells.
|
28635396 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The potential combinational effect of miR-34a with celecoxib in osteosarcoma.
|
28650862 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicated that NEAT1 participated in the development of osteosarcoma as a ceRNA to competitively bind to miR-34a-5p and thus mediate HOXA13 expression.
|
31044561 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several microRNAs including the miR-34 family have been implicated in osteosarcoma tumorigenesis via effects on the Notch signaling pathway.
|
26659003 |
2015 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-Regulated microRNA-34a Expression as a Prognostic Marker for Poor Osteosarcoma in Mice: A Systematic Review and Meta-Analysis.
|
30519318 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results demonstrated that miR-199a and miR-34a could induce the apoptosis of human osteosarcoma cells via p53 signalling pathway.
|
24957404 |
2014 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR-34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination.
|
28415566 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene.
|
28948006 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further exploration on the downstream network of miR-34a identified that blocking plasminogen activator inhibitor-1 (PAI-1) expression could restrain OS dedifferentiation into cancer stem-like cells by downregulating SRY-related-HMG box (Sox) 2.
|
29991717 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggested that miR-34a-5p, DLL1 and the ATF2/ATF3/ATF4 signaling pathway-associated genes are the potential diagnostic and/or therapeutic targets for an effective chemotherapy of OS.
|
28281638 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Validating the coordinating role of miR-34a in microtubule destabilization, when miR-34a was combined with either microtubule inhibitors or chemotherapy, STMN1 phosphorylation was suppressed and there was greater cytotoxicity in osteosarcoma cells.
|
28275089 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The angiotensin II type 1 receptor (AGTR1) gene, is one of the targets of miR-34a-5p in OS and thus negatively correlates with OS chemoresistance by systematic investigations of a multi-drug sensitive (G-292) and resistant (SJSA-1) OS cell lines.
|
28073349 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, in this study, using systematic observations of multi-drug sensitive (G-292 and MG63.2) and resistant (SJSA-1 and MNNG/HOS) osteosarcoma (OS) cell lines, we showed that miR-34a-5p promotes the multi-drug resistance of OS through the receptor tyrosine kinase CD117, a direct target of miR-34a-5p.
|
27056900 |
2016 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
And there are other putative miR-34a target genes beside c-Met which could potentially be key players in the development of osteosarcoma.
|
22457788 |
2012 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings find out an important function of miR-34a as a novel tumor-suppressor in osteosarcoma pathogenesis through inhibition of DUSP1.
|
29312491 |
2017 |
|
Osteosarcoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Expression of MiR-34s was decreased in tumor samples, and MiR-34 genes underwent minimal deletions and epigenetic inactivation in osteosarcomas.
|
19632201 |
2009 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of the transcription factor, runt-related transcription factor 2 (RUNX2), is a key pathological feature in osteosarcoma and associated with loss of p53 and miR-34 expression.
|
30637720 |
2019 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The oncogene role of SNHG7 in vivo was also confirmed and found that knockdown of SNHG7 delayed the tumor growth with increased miR-34a level and Ki-67 level in OS tissues.
|
29989838 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MREs of miR-34 and miR-122 ensured that the luciferase gene was expressed selectively in osteosarcoma cells.
|
25335093 |
2015 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that MALAT1 and CCND1 mRNA expression levels were upregulated and miR‑34a was downregulated in OS tissues and cells.
|
30365098 |
2019 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, it can be concluded that through the inhibition of CD44 expression levels, miR-34a plays a significant role in the migration and invasion of osteosarcoma cells.
|
23314380 |
2013 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of U2OS cells with cisplatin induced cell apoptosis by upregulation of c-Myc -dependent Bim expression; Osteosarcoma U2OS cells transfected with miR-34a mimics (miR-34a/U2OS) induced cell apoptosis and inhibited cell survival, and increased the sensitivity of U2OS cells to cisplatin.
|
29060932 |
2017 |